Compare Cassava Sciences Inc (FLNA) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Snowflake Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Snowflake Inc trades at $346 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 3074.9× Cassava Sciences Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Snowflake Inc for 54 Days on average.
| FLNA | SNOW | |
|---|---|---|
Market Cap | $39.40M | $121.15B |
Volume | 759,018 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $4.64 | $356.47 |
52-Week Low | $0.68 | $121.11 |
Typical Hold Time | 37 Days | 54 Days |
Enterprise Value | -$43.28M | $121.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Snowflake (SNOW) trades at $332.85, down 0.92% on the day, as the stock shows mixed technical signals with neutral overall momentum. Fundamentally, the company demonstrates strong revenue growth reaching $3.63 billion in 2025 but continues to post significant losses with a -20.07% net margin. Recent positive developments include three consecutive earnings beats and a strategic partnership expansion with UiPath, though the company faces investor concerns over a $3.75 billion convertible note offering announced in late September 2026.
Wall Street maintains strong bullish sentiment with 81% buy ratings and a $418.03 consensus price target representing 26% upside potential. The investment case hinges on Snowflake's position in the growing data cloud market and improving revenue trajectory, balanced against persistent profitability challenges and competitive pressures in the enterprise software sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
